Saravanan G., group managing director of Biocare Group, details the opportunities he identified to create the first MDI (Metered Dose Inhalers) manufacturing plant in Malaysia. He also explains further the support received by the government for his initiatives and how the company will continue its efforts to bring more innovative and affordable drugs in the Malaysian market.
Eight to ten percent of the population of Malaysia is affected by asthma. Currently, the respiratory segment is the leading growth driver of our company.
